IMP Relative Valuation - Imexpharm Corp - Alpha Spread
I

Imexpharm Corp
VN:IMP

Watchlist Manager
Imexpharm Corp
VN:IMP
Watchlist
Price: 49 000 VND -1.8%
Market Cap: 3.8T VND
Have any thoughts about
Imexpharm Corp?
Write Note

Relative Value

The Relative Value of one IMP stock under the Base Case scenario is 34 908.24 VND. Compared to the current market price of 49 000 VND, Imexpharm Corp is Overvalued by 29%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

IMP Relative Value
Base Case
34 908.24 VND
Overvaluation 29%
Relative Value
Price
I
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
1
vs Industry
40
Median 3Y
1.2
Median 5Y
1.1
Industry
2.6
Forward
1.6
vs History
1
vs Industry
21
Median 3Y
9.3
Median 5Y
8.2
Industry
22.9
Forward
12.4
vs History
6
vs Industry
Median 3Y
5.7
Median 5Y
7.8
Industry
17.6
vs History
vs Industry
Median 3Y
8.8
Median 5Y
10.6
Industry
25.2
vs History
1
vs Industry
29
Median 3Y
1
Median 5Y
0.9
Industry
2.2
vs History
1
vs Industry
39
Median 3Y
1.1
Median 5Y
1
Industry
2.7
Forward
1.6
vs History
1
vs Industry
31
Median 3Y
2.9
Median 5Y
2.5
Industry
5.4
vs History
1
vs Industry
29
Median 3Y
5.1
Median 5Y
4.8
Industry
13.9
Forward
7
vs History
1
vs Industry
28
Median 3Y
6.5
Median 5Y
5.8
Industry
17.3
Forward
8.6
vs History
6
vs Industry
Median 3Y
4.9
Median 5Y
7.7
Industry
16.1
vs History
1
vs Industry
Median 3Y
7.3
Median 5Y
6.9
Industry
18.8
vs History
1
vs Industry
30
Median 3Y
0.9
Median 5Y
0.9
Industry
2

Multiples Across Competitors

IMP Competitors Multiples
Imexpharm Corp Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
VN
Imexpharm Corp
VN:IMP
3.8T VND 1.8 15.8 8.5 11.2
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY 4 211 733 -5 347 888.9 -5 459 134.4 -5 046 864.6
US
Eli Lilly and Co
NYSE:LLY
843.2B USD 21.7 114.8 57.4 64.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
DK
Novo Nordisk A/S
CSE:NOVO B
3.4T DKK 13.3 38.2 25.5 29.2
US
Johnson & Johnson
NYSE:JNJ
385.8B USD 4.5 10.1 12.4 16.1
US
Merck & Co Inc
NYSE:MRK
278.3B USD 4.5 20.3 13.7 16.8
CH
Roche Holding AG
SIX:ROG
206.1B CHF 3.5 17.9 10.1 12
UK
AstraZeneca PLC
NASDAQ:AZN
240.2B USD 4.9 37.3 17.1 25.6
CH
Novartis AG
SIX:NOVN
191.2B CHF 4.6 13.8 10.9 16.1
US
Pfizer Inc
NYSE:PFE
162B USD 2.9 -62.4 12.6 20.4
P/E Multiple
Earnings Growth
VN
I
Imexpharm Corp
VN:IMP
Average P/E: 33.5
15.8
N/A
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 347 888.9 N/A
US
Eli Lilly and Co
NYSE:LLY
114.8
425%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A
DK
Novo Nordisk A/S
CSE:NOVO B
38.2
90%
US
Johnson & Johnson
NYSE:JNJ
10.1
-22%
US
Merck & Co Inc
NYSE:MRK
20.3
7 419%
CH
Roche Holding AG
SIX:ROG
17.9
30%
UK
A
AstraZeneca PLC
NASDAQ:AZN
37.3
175%
CH
Novartis AG
SIX:NOVN
13.8
19%
US
Pfizer Inc
NYSE:PFE
Negative Multiple: -62.4
712%

See Also

Discover More
Back to Top